Elucidating the inflammatory bowel disease where tiny has big impacts - Meet one of the Scipio bioscience’s grant awards winners! 🏅 For years, Dr. Rainer Glauben and Adrian Huck at Charité - Universitätsmedizin Berlin have been investigating a tiny, tricky, but key tissue in our guts, likely telling our immune system not to fight the food we eat. With his $30,000-worth prize covering Asteria™ scRNA-seq benchtop kits and sequencing, they can now dive further into the cellular composition of the Peyer’s Patches, decipher the role of different cell types, and hopefully figure out some of the causes of inflammatory bowel diseases such as Crohn’s disease. Read more about his research and the other winners here: https://lnkd.in/ewc_btYK #grant #singlecell #ibd
Scipio bioscience’s Post
More Relevant Posts
-
Did you miss our LabRoots webinar last week featuring Dr. Christoph Kuppe, MD, MHBA from RWTH Aachen University Hospital? Don't worry- it's now available on demand! Watch the webinar at any time to learn how MERFISH spatial transcriptomics with MERSCOPE can be applied to study both human heart and human kidney disease. Access the webinar here: https://hubs.ly/Q028J9wh0 #Vizgen #Webinar #MERSCOPE #MERFISH #SpatialTranscriptomics #SpatialGenomics #SpatialMultiomics #ProteinCoDetection #SingleCell #CellAtlas #HeartDisease #KidneyDisease #PrecisionMedicine
-
-
The 4th International Symposium on Interstitial Lung Disease (ILD) in Rheumatic Diseases will convene virtually on January 12-14. Intended for scientists and clinicians who focus on rheumatic diseases like #scleroderma, this meeting aims to draw attention to #ILD and share recent progress by the world's top researchers and clinicians. We're pleased to share that CONQUEST, the SRF-driven platform clinical trial, will be featured in this event. The goal of CONQUEST is to rapidly evaluate potential treatments for scleroderma-associated ILD. Dr. Dinesh Khanna of the University of Michigan (pictured right) and Dr. Toby Maher of Keck School of Medicine (pictured left), the co-chairs of the CONQUEST steering committee, will share a presentation that discusses this groundbreaking clinical trial. Through CONQUEST, the SRF is spurring vital therapeutic innovation. In short, it's a game-changer. We are so grateful for the opportunity to share this work with the greater scientific and medical community—collaboration is essential to making progress. ➡️ Learn more & register for the symposium: https://lnkd.in/gAhFadTn ➡️ Learn more about CONQUEST: https://lnkd.in/gex9KYwq #sclerodermaresearch #srfcure #conquest #sayscleroderma
-
-
Apply for the MMRF 2024 Research Fellows Award Program: This initiative aims to engage and support investigators exploring myeloma and its precursor conditions, advancing our understanding of disease biology, disease risk, treatment response, and relapse. https://lnkd.in/ejZRfdtt
-
-
Exciting news to share from the CII today!
The CII is excited to expand its efforts to illuminate Long COVID, continuing participation in the second phase of the Long COVID Research Consortium! Thanks to new funding from PolyBio Research Foundation, led by Amy Proal, a team of 5 stellar scientists will investigate the enigmatic mechanisms of SARS-CoV-2 viral persistence. The CII Director, Prof. Akiko Iwasaki joins efforts with Prof. Richard Flavell, Prof. Anna Marie Pyle, Prof. Craig Wilen and Prof. Scott Handley (Washington University) to pursue a bold and innovative project that aims to define the molecular structure of the persistent vRNA and test new therapeutic interventions in a novel mouse model developed by the Flavell Lab. Long COVID research is receiving a significant lift today, thanks to PolyBio's distribution of 15 Million dollars to this cause! Funds were allocated across a dozen institutions to interdisciplinary teams who have been leading progress in this field. Thank you for including our team in this exciting new effort to illuminate the root-causes of Long COVID !! Yale University School of Medicine Press Release: https://lnkd.in/eSk5XtJg
-
🚀 Exciting Breakthrough in Crohn’s Disease Research! 🧬 Researchers from the University of Cambridge have made significant strides in understanding #Crohn’s disease by growing over 300 "mini-guts" or organoids in the lab [https://lnkd.in/gZnSWujB] This innovative approach is shedding new light on this lifelong inflammatory bowel disease affecting 1 in 350 people in the UK. Key Highlights: 🔬 Epigenetic Differences: Epithelia in Crohn’s patients show distinct epigenetic patterns compared to healthy individuals. 📈 Correlation with Disease Severity: These epigenetic changes are linked to the severity of the disease, offering potential markers for disease progression. 🦠 Immune Pathway Activity: Increased activity of the major histocompatibility complex-I (MHC-I) pathway was observed, which is crucial for immune response and inflammation. Led by Professor Matthias Zilbauer, the team’s research offers hope for developing and testing new, personalized treatments for Crohn’s disease. This groundbreaking work not only enhances our understanding of the disease but also opens the door to more effective therapies tailored to individual patients! Kudos to the University of Cambridge team for their dedication and innovation! 🌟 #HealthcareInnovation #MedicalResearch #CrohnsDisease #IBD #Epigenetics #PersonalizedMedicine #CambridgeUniversity #Biotechnology #HealthTech
-
Apply for the MMRF 2024 Research Fellows Award Program: This initiative aims to engage and support investigators exploring myeloma and its precursor conditions, advancing our understanding of disease biology, disease risk, treatment response, and relapse. https://lnkd.in/eB5A_zi9
-
-
🌟#notablepaper on #ParkinsonsDisease #WorldParkinsonsDiseaseDay 📚Alpha-Synuclein Autoimmune Decline in Prodromal Multiple System Atrophy and Parkinson’s Disease 🔗https://lnkd.in/gN67wxu8 👨🔬By Dr. Jonas Folke et al MDPI Department of Clinical Research, Amager and Hvidovre Hospital Københavns Universitet - University of Copenhagen #multiplesystematrophy #nAbs #autoantibodies #alphasynuclein #prodromal
-
-
Save the date! July 17, 2024: Front Row Lecture with Michael Bollong Regenerative medicine involves harnessing the body’s capacity to repair tissues and organs. Join us on Wednesday, July 17, as Associate Professor Michael Bollong shares how he is identifying and targeting the pathways controlling regeneration, and developing novel medicines to intervene in the processes that cause a spectrum of human diseases, including heart disease, inflammatory disease and fibrosis. #medicine #heartdisease #fibrosis Register here ⬇
Regenerating tissues to treat disease: Michael Bollong, PhD - Scripps Research
https://frontrow.scripps.edu
-
Scientific inspiration can come from the most unexpected places. For National Institute of Dental and Craniofacial Research (NIDCR)'s Dr. Eva Mezey, dinner with a friend and fellow scientist whose lab focused on fish helped jumpstart the discovery of bone marrow cells that can make a substance capable of fighting infections and regulating overactive immune responses. Learn more about the #NIH_IRP research that led to this discovery: https://go.nih.gov/3bgeLYq
-
-
New Model Available for #Parkinson’s Disease Research! ✔️Avoid Developmental Compensation ✔️No Licensing Required to Obtain Mice ✔️Validated in Several Key Studies Discover how the Floxed Parkin mouse model can accelerate advancements in your research program: https://bit.ly/3VLQtyy
New Parkinson's Disease Research Model: Floxed Parkin Mouse | Taconic Biosciences
taconic.com
